SCHEMBL4121432

SCHEMBL4121432

CCOc1cccc(NC(=O)Nc2ccc(F)c(F)c2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.59
SMN1; SMN2 Q16637 6/20 0.57
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
PAX8 Q06710 2/20 0.57
MITF O75030 1/20 0.57
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
ALDH1A1 P00352 2/20 0.55
HTT P42858 1/20 0.55
HSD17B10 Q99714 1/20 0.55
MAPT P10636 4/20 0.55
PKM P14618 1/20 0.55
BRAF P15056 1/20 0.54
TSHR P16473 2/20 0.53
HPGD P15428 1/20 0.53
TP53 P04637 1/20 0.52
NR1H4 Q96RI1 1/20 0.51
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118137 0.90 SMN1; SMN2 (0.56) EPHX2SMN1; SMN2NPC1RAB9APAX8
SCHEMBL4110798 0.90 NPC1 (0.57) EPHX2SMN1; SMN2NPC1RAB9APAX8
SCHEMBL4107028 0.89 SMN1; SMN2 (0.64) EPHX2SMN1; SMN2NPC1RAB9APAX8
SCHEMBL4112076 0.87 MAPT (0.70) SMN1; SMN2NPC1RAB9APAX8MITF
SCHEMBL4104631 0.86 KMT2A (0.59) SMN1; SMN2NPC1RAB9APAX8MITF
SCHEMBL4111978 0.86 NPC1 (0.75) SMN1; SMN2NPC1RAB9APAX8MITF
SCHEMBL4106738 0.85 NPC1 (0.64) EPHX2SMN1; SMN2NPC1RAB9APAX8
SCHEMBL4118181 0.85 HTT (0.56) SMN1; SMN2NPC1RAB9APAX8MITF
SCHEMBL4112735 0.84 NPC1 (0.68) SMN1; SMN2NPC1RAB9APAX8MITF
SCHEMBL4118559 0.83 MEN1 (0.66) SMN1; SMN2NPC1RAB9APAX8MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 EPHX2 2394/4885SMN1; SMN2 4056/4885NPC1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.